EPISODE · Apr 15, 2021 · 5 MIN
FDA Approves Umbralisib for Marginal Zone Lymphoma, Follicular Lymphoma
from Rare Disease Discussions · host CheckRare Editors
Owen A. O’Connor, Chief Scientific Officer at TG Therapeutics, discusses umbralisib, which was approved for the treatment of relapsed or refractory follicular lymphoma (FL) and relapsed or refractory marginal zone lymphoma (MZL)Rare Discussions is produced by CheckRare, the leading multimedia platform dedicated to advancing education, awareness, and innovation across the rare disease community.Explore additional physician interviews, podcasts, CME activities, and rare disease resources at CheckRare.com.Subscribe to the CheckRare Podcast Network for expert conversations, weekly news, accredited education, and the latest advances across the rare disease community.Part of the CheckRare Podcast Network: Trusted conversations, news, education, and expert insights across the rare disease community.
Embed this episode
NOW PLAYING
FDA Approves Umbralisib for Marginal Zone Lymphoma, Follicular Lymphoma
No transcript for this episode yet
Similar Episodes
No similar episodes found.